Share Price | Aura Biosciences, Inc. Stock Analysis & Recommendation

Q: What does Aura Biosciences, Inc. do?

Overview:Aura Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot:- Most recent Net Profit: -27 Million (Quarterly Results - Mar 2025)- Market-cap: USD 383.19 Million (Micro Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -0.98- Return on Equity: -74.00%- Price to Book: 2.99Contact Details:Details: No Company Details AvailableRegistrar Address: Not available.

Q: Is Aura Biosciences, Inc. technically bullish or bearish?

As of 21 May 2025, the technical trend for Aura Biosciences, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearish momentum, while the weekly MACD shows a mildly bullish signal. However, the Bollinger Bands and OBV on both weekly and monthly time frames are mildly bearish, contributing to the overall bearish sentiment. In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -23.84% versus the S&P 500's 12.22%, and a one-year return of -34.45% compared to 17.14% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

189.9 k

Shareholding (Sep 2025)

FII

18.27%

Held by 40 FIIs

DII

43.17%

Held by 28 DIIs

Promoter

16.50%

How big is Aura Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Aura Biosciences, Inc. has a market capitalization of 383.19 million and reported net sales of 0.00 million with a net profit of -94.69 million over the last four quarters. Shareholder's funds are 151.97 million, and total assets amount to 182.50 million.

View full answer

What does Aura Biosciences, Inc. do?

22-Jun-2025

Aura Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $27 million and a market cap of $383.19 million. The company has no dividend yield and negative return on equity.

View full answer

Is Aura Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of May 21, 2025, Aura Biosciences, Inc. has shifted to a mildly bearish trend, with daily moving averages indicating bearish momentum, while underperforming the S&P 500 significantly with a year-to-date return of -23.84% compared to the index's 12.22%.

View full answer

Compare Aura Biosciences, Inc. with Similar Stocks

Voyager Therapeutics, Inc.Precigen, Inc.Aldeyra Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 340 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-67.96%

Price to Book

2.17

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-26 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-5.63%

6 Months

-18.91%

1 Year

-33.0%

2 Years

-31.02%

3 Years

-47.09%

4 Years

-70.29%

5 Years

0.0%

Aura Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-224.91%

EBIT to Interest (avg)

-74.94

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.98

Sales to Capital Employed (avg)

Tax Ratio

0.09%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

93.37%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.15

EV to EBIT

-2.71

EV to EBITDA

-2.74

EV to Capital Employed

88.40

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-3267.75%

ROE (Latest)

-74.00%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 30 Schemes (22.06%)

Foreign Institutions

Held by 40 Foreign Institutions (18.27%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -24.29% vs -13.51% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.60",
          "val2": "-22.90",
          "chgp": "-20.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.10",
          "val2": "-21.00",
          "chgp": "-24.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -13.74% vs -29.93% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-94.90",
          "val2": "-83.70",
          "chgp": "-13.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-86.90",
          "val2": "-76.40",
          "chgp": "-13.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-27.60

-22.90

-20.52%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-26.10

-21.00

-24.29%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -24.29% vs -13.51% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-94.90

-83.70

-13.38%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-86.90

-76.40

-13.74%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -13.74% vs -29.93% in Dec 2023

All Annual Results

Company CV

About Aura Biosciences, Inc.

Aura Biosciences, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Aura Biosciences, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Aura Biosciences, Inc.?

Watch in Real-Time

What does Aura Biosciences, Inc. do?

Is Aura Biosciences, Inc. technically bullish or bearish?

Compare Aura Biosciences, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Aura Biosciences, Inc.

Company Coordinates